Transcriptomic Analysis in a Model of Aniridia-Associated Keratopathy for Target Discovery and Evaluation of Duloxetine Therapy.

ABSTRACT:

Purpose

Aniridia-associated keratopathy (AAK) leads to loss of corneal transparency because of epithelial, inflammatory, and pathological vascular changes. Here, we sought to understand this process at the transcriptomic level while evaluating an experimental pharmacotherapy for potential modulatory effects.

Method

17 Pax6+/- Small-eye (Sey) heterozygous mice with p.Gly208* Pax6 mutation and 10 wild-type 129S1/SvImJ mice at four months of age were examined to identify dysregulated genes and pathways in established AAK. We next evaluated the potential efficacy of 10 µM duloxetine administered as eye drops twice daily for 90 days, assessing outcomes at the transcriptomic level via microarray and protein level with Western blot and immunostaining.

Results

Transcriptomic

SUBMITTER: Javidjam D 

PROVIDER: S-EPMC12814980 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature